Skip to main content

Table 4 Univariate and multivariate analyses for all-cause readmission in the HF + COPD group

From: Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction

 

Univariate analysis

Multivariate analysis

HR

95% CI

p-value

HR

95% CI

p-value

Age (years)

0.995

(0.968–1.023)

0.732

   

Male

1.265

(0.598–2.676)

0.594

   

Smoking

1.440

(0.652–3.182)

0.367

   

BMI (kg/m2)

0.991

(0.926–1.060)

0.785

   

Hypertension

1.986

(0.718–5.498)

0.187

   

DM

1.226

(0.704–2.135)

0.471

   

CAD

1.554

(0.918–2.630)

0.101

   

Dyslipidemia

1.725

(0.972–3.062)

0.062

1.450

(0.798–2.632)

0.222

CKD

1.137

(0.661–1.955)

0.642

   

Afib

1.066

(0.613–1.853)

0.822

   

Stroke

2.773

(1.217–6.318)

0.015*

2.881

(1.244–6.672)

0.014*

Hemoglobin

(g/dL)

1.001

(0.893–1.121)

0.992

   

Creatinine

(μmol/L)

0.906

(0.698–1.175)

0.457

   

BNP > 1210 pg/mL

1.051

(0.616–1.793)

0.856

   

LVEF (%)

1.001

(0.968–1.035)

0.949

   

β1-blocker

1.489

(0.795–2.789)

0.213

   

Nonselective BB

1.025

(0.502–2.090)

0.946

   

ACEI/ARB

0.836

(0.493–1.420)

0.508

   

MRA

1.063

(0.627–1.801)

0.820

   

LABA

1.433

(0.849–2.421)

0.178

   

LAMA

1.120

(0.651–1.927)

0.682

   

ICS

1.372

(0.794–2.368)

0.257

   

OCS

3.918

(1.654–9.285)

0.002*

3.824

(1.566–9.335)

0.003*

  1. Variables that met the significance level of 0.10 were included in the multiple regression model
  2. BMI body mass index, DM diabetes mellitus, CAD coronary artery disease, CKD chronic kidney disease, BB β-blocker, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, MRA mineralocorticoid receptor antagonist, LABA long-acting β agonist, LAMA long-acting muscarinic antagonist, ICS inhaled corticosteroid, OCS oral corticosteroid, Afib atrial fibrillation, EF ejection fraction
  3. *p-value < 0.05 indicates statistical significance